Abstract
Background: To elucidate the pathomechanisms of and to develop potential therapies for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and the polyglutamine (polyQ) diseases, various rodent models have been developed so far. However, they have limitations in the translational research owing to the differences in the brain structure and functions, and drug metabolism between humans and rodents. Therefore, clinically-relevant non-human primate models of neurodegenerative diseases have been eagerly anticipated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
